Technology
Health
Pharmaceutical

Verona Pharma

$6.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.32 (5.41%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Verona Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. It's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Read More The firm develops RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, United Kingdom.

Employees
Headquarters
London, Greater London
Founded
2005
Market Cap
77.81M
Price-Earnings Ratio
Dividend Yield
Average Volume
6.50K
High Today
$6.23
Low Today
$5.91
Open Price
$5.91
Volume
1.31K
52 Week High
$17.16
52 Week Low
$5.52

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Therapy
2017 IPO
UK

News

Yahoo FinanceMay 7

Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials

LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a Phase 2b dose-ranging study evaluating nebulized ensifentrine (RPL554) added on to a long acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (“COPD”). The Company anticipates reporting data around year end and commencing Phase 3 clinical trials for this indication in ...

25
Markets InsiderMay 1

Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker

LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to announce the appointment of Nplus1 Singer Advisory LLP (together with its associates, "N+1 Singer") as nominated adviser and UK corporate broker to the Company with immediate effect.

11
Markets InsiderMay 1

Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update

LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the first quarter ended March 31, 2019 on Tuesday, May 7, 2019. Verona Pharma will host an investment community conference call at 8:00 a.m. Eastern Daylight Time (1:00 p.m. British Summer Time) on Tuesday, May 7, 2019 to discuss the first quarter financial results...

8

Earnings

-$0.93
-$0.62
-$0.30
$0.01
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.